Glucagon Like Peptide-1 (GLP-1) Agonists Market , by Type (Short-acting GLP-1 Agonists, Long-acting GLP-1 Agonists) , by Route of administration (Parenteral, Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Key Market Dynamics 

The Glucagon like peptide-1 (GLP-1) agonists market growth is driven by several key factors, with the rising global prevalence of type 2 diabetes and obesity being the most significant drivers. As lifestyle-related diseases surge due to sedentary behavior, poor diet, and aging populations, the demand for effective treatments like GLP-1 agonists grows. These drugs not only help manage blood glucose levels but also aid in weight loss, making them a dual-purpose treatment for diabetes and obesity. Additionally, advancements in drug formulations, such as once-weekly injectable options and combinations with insulin, enhance patient adherence and boost market adoption. The increasing geriatric population and growing awareness around the long-term health benefits of early diabetes management further fuel the market’s expansion. 

However, despite the promising growth, the market faces several restraints. High costs associated with GLP-1 agonist therapies limit their accessibility, particularly in low-income regions where healthcare budgets are strained. Additionally, side effects such as gastrointestinal issues, including nausea and vomiting, may deter some patients from using these medications, restricting their uptake. Regulatory challenges, including the approval process for new drug formulations, also pose a hurdle for market players aiming to innovate and expand their product lines. 

Furthermore, the potential of GLP-1 agonist in addressing non-alcoholic fatty liver disease (NAFLD) and as part of weight management therapies provides new avenues for growth. Increased investment in clinical research and broader insurance coverage for GLP-1 therapies in emerging markets could also help overcome cost barriers and open up new segments, driving future expansion of the Glucagon like peptide-1 (GLP-1) agonists market growth. 

Impaired fasting glucose (IFG) prevalence estimates (2030)  

The rising prevalence of Impaired Fasting Glucose (IFG) , a significant risk factor for developing type 2 diabetes, is expected to drive demand for GLP-1 agonists by 2030. According to the International Diabetes Federation, regions like South-East Asia (109, 400) and Africa (55, 200) will see substantial IFG cases, leading to increased diabetes risk. Similarly, high IFG prevalence in South and Central America (54, 300) and the Western Pacific (54, 100) highlights the growing need for effective glucose management therapies. As more individuals progress from IFG to type 2 diabetes, GLP-1 agonists, known for their efficacy in managing diabetes and aiding in weight loss, will be in higher demand across these regions.

Impaired fasting glucose (IFG) prevalance estimates (2030)- Thousands

Market Segmentation 

The glucagon like peptide-1 (GLP-1) agonists industry is segmented into type, route of administration, distribution channel and region. On the basis of type, the market is categorized into short-acting GLP-1 Agonists, and Long-acting GLP-1 Agonists. The Short-acting GLP-1 Agonists segment is divided into Exenatide and Lixisenatide. The long-acting GLP-1 Agonists segment is divided into Liraglutide, Dulaglutide, Semaglutide, and others. On the basis of route of administration, the market is segmented into parenteral and oral. On the basis of Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

Regional/Country Market Outlook 

The Glucagon Like Peptide-1 (GLP-1) Agonists Market size shows significant growth potential across major regions. In North America, the market is driven by the high prevalence of diabetes and obesity, along with strong healthcare infrastructure and favorable reimbursement policies. Europe follows closely, supported by rising awareness and advanced healthcare systems. The Asia-Pacific region presents substantial opportunities due to the increasing diabetic population, growing healthcare investments, and improving access to treatments in countries like China and India. Emerging markets in Latin America and Middle East & Africa are also witnessing growth, driven by urbanization and increasing diagnosis rates

Industry Trends

• National Institute for Health and Care Excellence issued draft guidance?recommending new drug  Semaglutide for adults with at least one weight-related condition? (such as high blood pressure, type 2 diabetes, or high cholesterol) . The drug suppresses appetite by mimicking the hormone glucagon-like peptide-1 (GLP-1) , which is released after eating. It makes people using it feel full, thereby resulting in people eating less and reducing their overall calorie intake.

Competitive Landscape

The major players operating in the Glucagon like peptide-1 (GLP-1) agonists market share include Novo Nordisk, Sanofi,  Eli Lilly Company, AstraZeneca, Boehringer Ingelheim International GmbH., Pfizer Inc., Oramed, ?Merck & Co., Inc., GSK plc., Amgen Inc.

Recent Key Strategies and Developments

• In May 2022, Eli Lilly and Company's?announced the?U.S. Food and Drug Administration? (FDA) approval for Mounjaro (tirzepatide) injection. It is new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
• In December 2023, Carmot Therapeutics Inc. (Carmot) , a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, announced that it has entered into a definitive merger agreement for Roche to acquire Carmot at a purchase price of $2.7 billion upfront and the potential for $400 million in milestone payments.

Key Sources Referred

• International Diabetes Federation
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• American Diabetes Association (ADA)
• Diabetes Canada
• Asian Association for the Study of Diabetes (AASD)
• Australian Diabetes Society (ADS)
• World Obesity Federation
• OECD Health Statistics
• Juvenile Diabetes Research Foundation 
• European Association for the Study of Diabetes (EASD)

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the glucagon like peptide-1 (GLP-1) agonists market analysis from 2024 to 2033 to identify the prevailing Glucagon Like Peptide-1 (GLP-1) Agonists Market opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the glucagon like peptide-1 (GLP-1) agonists market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends, key players, market segments, application areas, and market growth strategies.